Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Abraxis BioScience, Inc.
New Data Highlighting the Potential Utility of ABRAXANE in Combination with Targeted Therapies and Other Chemotherapeutic Agents to Be Presented at ASCO
June 6th, 2008
Abraxis BioScience, Inc. (NASDAQ:ABII), an integrated, global biopharmaceutical company, announced that multiple studies of ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 30-June 3, 2008. Data will be presented from studies highlighting the potential utility of ABRAXANE (ABI-007) in combination with the targeted agents bevacizumab and trastuzumab, and other chemotherapeutic agents, for neoadjuvant and first-line treatment of metastatic breast cancer. The U.S. Food and Drug Administration...
Source: Health Business Week (2008-06-06)
|
